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Abstract
Metabolites of neural cells, is known to have a significant effect on the normal physiology and function of neurons in brain.
However, whether they play a role in pathogenesis of neurodegenerative diseases is unknown. Here, we show that metabolites
of neurons play essential role in the pathogenesis of Alzheimer’s disease (AD). Firstly, in vivo and in vitro metabolites of
cerebellarneuronsbothsignificantly induced the expressionofAb-degradingenzymesinthe hippocampusandcerebralcortex
and promoted Ab clearance. Moreover, metabolites of cerebellar neurons significantly reduced brain Ab levels and reversed
cognitive impairments and other AD-like phenotypes of APP/PS1 transgenic mice, in both early and late stages of AD
pathology. On the other hand, metabolites of hippocampal neurons reduced the expression of Ab-degrading enzymes in the
cerebellum and caused cerebellar neurodegeneration in APP/PS1 transgenic mice. Thus, we report, for the first time, that
metabolites of neurons not only are required for maintaining the normal physiology of neurons but also play essential role in
the pathogenesis of AD and may be responsible for the regional-specificity of Ab deposition and AD pathology.
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Introduction
The fluid environment of neurons, which contains metabolites
of neural cells, is known to have a significant effect on the normal
physiology and function of neurons in brain [1]. For example,
neurotrophic factors, which are secreted by target tissue and
neural cells, can prevent the associated neurons from initiating
programmed cell death and thereby allow them to survive [2,3].
However, little is known about the role of metabolites of neurons
in the pathogenesis of neurodegenerative diseases.
Alzheimer’s disease (AD) is a progressive neurodegenerative
disease and the major cause of dementia among seniors. There are
more than 4 million people suffering from AD in the USA and 12
million worldwide. Ten percent of Americans over the age of 65
and half of those over 85 have AD [4,5]. AD pathology is
characterized by amyloid deposits in certain regions of the brain,
such as the entorhinal cortex, hippocampus and basal forebrain.
All of these areas are small, specialized structures in the brain that
play critical roles in memory [6,7]. However, the cerebellum is
spared from significant amyloid-b (Ab) accumulation and
neurotoxicity induced by Ab, even though Ab is present
throughout the brain [8]. Even in the AD-damaged regions, the
pathology is not ubiquitous. For example, the CA1 and the SB
regions of the hippocampus are vulnerable to AD, whereas the
CA3 region is resistant to AD [9]. Neuronal loss in CA1 area of
the hippocampus is demonstrated to be correlated with the
duration and severity of AD [10,11]. In cerebellum, Ab does not
deposit as senile plaques but as diffuse plaques composed of
nonfibrillar Ab [12]. It has also been reported that cerebellar
neurons are more resistant to soluble oligomeric Ab an Ab species
with potent neurotoxic activities [13], than the cortex and
hippocampus, which are vulnerable to AD [14]. However, little
is known about the physiological mechanism underlying the
regional specificity of Ab accumulation.
In the present study, we investigated whether the metabolites of
neurons in their fluid environment contribute to the pathogenesis
of AD.
Results and Discussion
Results
Metabolites of cerebellar neurons induced expression of
Ab degrading enzymes and promoted Ab clearance in
hippocampal neurons. We first found that expression of Ab
degrading enzymes, neprilysin (NEP) and insulin degrading
enzyme (IDE) in hippocampal neurons was induced by exposure
to conditioned medium from cerebellar neurons (C-CM) , which
contains metabolites of cerebellar neurons, compared to treatment
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containing hippocampal neuron metabolites (Figure 1A and B).
Moreover, injection of concentrated C-CM to the lateral ventricle
of SD rats also induced IDE and NEP expression (Figure 1C).
Secondly, clearance of exogenous Ab by primary hippocampal
neurons was significantly facilitated by the addition of C-CM,
compared to treatment with H-CM via Ab degradation by IDE
and NEP (Figure 1D and E). C-CM also protected hippocampal
neurons from Ab neurotoxicity compared to H-CM and fresh
medium (N-CM), which does not contain any neuronal metabolite
Figure 1. Metabolites of cerebellar neurons induced expression of Ab degrading enzymes and promoted Ab clearance in
hippocampal neurons. (A) Western blot analysis of NEP and IDE expression in hippocampal neurons treated with conditioned medium. (B) Real-
time PCR analysis of NEP and IDE expression in hippocampal neurons treated with conditioned medium (*P,0.05). (C) Real-time PCR analysis of gene
expression in the hippocampus of SD rats treated with conditioned medium (*P,0.05). (D) The Ab1-40 ELISA result shows that the decrease in Ab
(initial concentration of Ab1-40 monomers was 2 mg/ml) was significantly accelerated by C-CM compared to H-CM (P,0.01). (E) The Ab1-40 ELISA result
shows that inhibitor of NEP (Thiorphan, Th; 10 mM) and IDE (Bacitracin, Ba; 0.5 mg/ml) attenuated the promotion of Ab clearance by C-CM (P=0.001
and P,0.0005, respectively). (F) Cell activity was optically measured as a reduction of the MTT dye uptake by viable cells after a 48 h exposure to Ab
in the presence of C-CM, H-CM or N-CM (*** P,0.005).
doi:10.1371/journal.pone.0005530.g001
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neurons as opposed to hippocampal neurons (data not shown).
These results suggest that C-CM, which contains metabolites of
cerebellar neurons, promoted Ab clearance by inducing
expression of Ab degrading enzymes in hippocampal neurons
and protected hippocampal neurons from Ab neurotoxicity.
Metabolites of cerebellar neurons reduced Ab levels in the
hippocampus of APP/PS1 transgenic mice. Next,
concentrated C-CM was injected into the lateral ventricle of
APP/PS1 transgenic mice, which were known as AD models, to
investigate its effect on endogenous Ab levels. APP/PS1 mice
injected with H-CM were used as negative controls and mice
injected with concentrated N-CM were used as blank controls.
The levels of both soluble and insoluble Ab in the hippocampus of
APP/PS1 mice injected with C-CM were markedly reduced two
weeks after treatment compared to those in control mice. Because
brain Ab1-42 levels in APP/PS1 mice were much lower than Ab1-40
levels, we only compared Ab1-40 levels in the ELISA analysis.
Moreover, metabolites of cerebellar neurons also reduced the
numbers and mean sizes of senile plaques in the hippocampus of
APP/PS1 transgenic mice (Table 1; Figure 2A and B). Similar
results were recorded for cortical Ab levels (Table S1). Our results
demonstrate that metabolites of cerebellar neurons reduced brain
Ab levels in APP/PS1 transgenic mice. We also found that
metabolites of rat cerebellar neurons significantly decreased steady
state levels of Ab in hippocampus of normal SD rats (data not
shown), which suggests a consensus function of metabolites of
cerebellar neurons.
Metabolites of cerebellar neurons reversed Alzheimer’s
disease-like phenotypes of APP/PS1 transgenic mice. Next,
we explored whether the reductioninbrain Ab levelsby metabolites
of cerebellar neurons could eventually improve the cognitive
function of APP/PS1 transgenic mice. The Morris Water Maze
(MWM)wasusedtotestlearningand memory.At12monthsofage,
APP/PS1 mice were significantly impaired in cognitive function
compared with age-matched wild-type mice. Treated with C-CM
had significant behavioral improvement compared to APP/PS1
mice treated with either H-CM or N-CM (P,0.01; Figure 2C).
Probe trials, in which the platform was removed and mice were
given1 mintoexplorethepool,confirmed the beneficialeffectofC-
CM (Figure 1D and E). Thus, C-CM ameliorates water maze
learning and memory deficits.
A passive avoidance test was also performed to examine
learning and memory. Inspection of the results indicated that
retention latency was higher than training latency, which is
indicative of memory formation, in all groups (Figure 2F). The
retention latency in APP/PS1 mice treated with C-CM was
significantly higher than that in APP/PS1 mice treated with either
H-CM or N-CM (Figure 2F).
These behavioral improvements were accompanied by im-
provements in other Alzheimer’s disease-like neuropathology
including glial reaction and synaptic loss. C-CM decreased both
the astrogliotic response (P,0.01) and microglial activation
(P,0.05; Figure 2G), compared to N-CM and H-CM treatment.
Synaptic loss presumably reflects the chronic synaptotoxic effects
of Ab oligomers. Measurement of synaptophysin levels in the
hippocampus showed that C-CM increased the number of
syanptophysin-reactive boutons and cell bodies compared to N-
CM and H-CM (P,0.01; Figure 2H). These results show that
metabolites of cerebellar neurons reversed the Alzheimer’s disease-
like phenotypes of APP/PS1 transgenic mice.
In vivo metabolites of cerebellar neural cells reversed
Alzheimer’s disease-like phenotypes of APP/PS1 transgenic
mice. Since the cerebrospinal fluid of the fourth ventricle (CSF-
4V) contains in vivo metabolites of cerebellar neural cells, we
collected CSF-4V from wild-type mice and injected this into the
lateral ventricle of APP/PS1 transgenic mice. CSF of the lateral
ventricle (CSF-LV) was also collected and injected as a control.
Injection of CSF-4V significantly reduced levels of both soluble and
insoluble Ab (Table 1; Figure 3A) and the numbers and mean sizes
of senile plaques in the hippocampus of APP/PS1 transgenic mice
(Figure 3B). Similar results were obtained in APP/PS1 mice at 12
months and 4 months, which are the late and early stages of AD
pathology, respectively. We also found that CSF-4V from rat brains
significantly decreased steady state levels of Ab in hippocampus of
normal SD rats (data not shown), which suggests a consensus
function of CSF-4V. APP/PS1 mice, aged either 12 months or 4
months, exhibited significant memory improvement and better
maze learning when they were treated with CSF-4V compared to
mice treated with CSF-LV (P,0.05; Figure 3C). Probe trials, in
which the platform was removed and mice were given 1 min to
explore the pool, confirmed the beneficial effect of CSF-4V
(Figure 3D and E). The retention latency of the passive avoidance
test in APP/PS1 mice treated with CSF-4V was significantly higher
than that in those treated with CSF-LV (Figure 3F).
The behavioral improvements after CSF-4V treatment were
accompanied by improvements in other Alzheimer’s disease-like
neuropathology such as astrogliotic response, microglial activation
(Figure 3G), and synaptic loss (Figure 3H), compared to CSF-LV.
Table 1. Metabolites of cerebellar neurons decrease Ab levels and plaques in hippocampus.
Ab1-40 (ng/g wet brain6s.e.m) Total plaque area (mm2) Mean plaque size (mm2)
Soluble Insoluble
N-CM 45,3506609 78,11064258 351,74964655 420620
H-CM 45,78161090 108,19563354 342,23661817 458622
C-CM 24,3386905
# 35,89761449** 172,94268206** 19464*
12-month LV 47,8006480 107,67062173 298,23367653 323613
12-month 4V 27,4176953
# 35,71861996
# 127,26163635
# 17665**
4-month LV 22,2846667 37,61161172 26,689 61281 8666
4-month 4V 15,2066849** 16,42761504
# 11,0146890** 4567*
#P,0.001.
**P,0.01.
*P,0.05.
doi:10.1371/journal.pone.0005530.t001
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reversed Alzheimer’s disease-like phenotypes of APP/PS1 trans-
genic mice in both early and late stages of AD pathology.
Metabolites of hippocampal neurons reduced Ab-
degrading enzymes expression and caused cerebellar
neurodegeneration in APP/PS1 transgenic mice. On the
Figure 2. Metabolites of cerebellar neurons reversed Alzheimer disease-like phenotypes of APP/PS1 transgenic mice. (A) Thioflavin-S
staining of hippocampal amyloid plaques in APP/PS1 mice (**P,0.01). (B) Immunostaining of hippocampal Ab deposits in APP/PS1 mice (n=6 to 10
mice per treatment group; age 12 months) (*P,0.05). (C) Cued platform learning curves show that APP/PS1 mice treated with C-CM had significant
behavioral improvement compared to mice treated with either H-CM or N-CM (P,0.01). (D) Representative path tracings of probe trials after 4 days
of training. (E) Number of target platform crossings versus crossings of the equivalent area in the three other quadrants. (F) Latencies to step through
into the shock compartment on the training trial and retention trial of the passive avoidance test. (G) C-CM decreased both the astrogliotic response
(**P,0.01) and microglial activation (*P,0.05). (H) C-CM increased the number of syanptophysin-reactive boutons and cell bodies compared to N-
CM and H-CM (***P,0.005; n=6 to 10 mice per treatment group; age 12 months).
doi:10.1371/journal.pone.0005530.g002
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of hippocampal neurons, significantly reduced the expression of
IDE and NEP in cerebellar neurons (Figure 4A). Moreover,
injection of concentrated H-CM and CSF from the lateral
ventricle to the fourth ventricle of APP/PS1 transgenic mice
induced cerebellar Ab levels (Figure 4B and C) and and astrogliosis
(data not shown) compared with injection of C-CM after one week
of injection.
Cerebellum is important for coordinated movement and
balance. Thus, pole test and balance beam test were performed
to measure cerebellar function of these mice after one week of H-
CM treatment. The behavioural function of APP/PS1 mice
Figure 3. In vivo metabolites of cerebellar neurons reversed Alzheimer’s disease-like phenotypes of APP/PS1 transgenic mice. (A)
Thioflavin-S staining of hippocampal amyloid plaques in APP/PS1 mice (
#P,0.01). (B) Immunostaining of hippocampal Ab deposits in APP/PS1 mice
(*P,0.05, **P,0.01). (C) Cued platform learning curves showed that APP/PS1 mice treated with CSF-4V exhibited significant behavioral improvement
compared to mice treated with CSF-LV (P,0.05). (D) Representative path tracings of probe trials after 4 days of training. (E) Number of target
platform crossings versus crossings of the equivalent area in the three other quadrants. (F) Latencies to step through into the shock compartment on
the training trial and retention trial of the passive avoidance test. (G) CSF-4V decreased both the astrogliotic response and microglial activation
(*P,0.05, **P,0.01). (H) C-CM increased the number of syanptophysin-reactive boutons and cell bodies compared to N-CM and H-CM (*P,0.05;
n=6 to 10 mice per treatment arm; age 4 months or 12 months).
doi:10.1371/journal.pone.0005530.g003
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(Figure 4D) and balance beam test (Figure 4E), indicating
disturbed balance and cerebellar dysfunction compared with these
mice treated with C-CM. These results demonstrated that
metabolites of hippocampal neurons caused cerebellar neurode-
generation in AD mice.
Figure 4. Metabolites of hippocampal neurons reduced Ab-degrading enzymes expression and caused cerebellar neurodegen-
eration in APP/PS1 transgenic mice. (A) Western blot analysis of NEP and IDE expression in cerebellar neurons treated with conditioned medium.
(B) The Ab1-40 ELISA result shows that H-CM induced cerebellar Ab levels compared with C-CM. (C) Injection of CSF from the lateral ventricle (LV)
induced cerebellar Ab levels compared with CSF from the fourth ventricle (4V) (*P,0.05, ** P,0.01). (D) Motor function of APP/PS1 mice treated with
H-CM was impaired in a pole test and (E) balance beam test (n=6 to 11).
doi:10.1371/journal.pone.0005530.g004
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Our findings highlight, for the first time, the role of metabolites
of neurons in the pathogenesis of Alzheimer’s disease. On the one
hand, metabolites of cerebellar neurons could protect against AD,
while on the other hand, metabolites of hippocampal neurons
facilitate AD pathogenesis.
In detail, metabolites of cerebellar neurons reduce Ab
accumulation by inducing Ab degrading enzymes. A previous
report shows that IDE and NEP levels in cerebellum are
significantly higher than those in hippocampus and selectively
decreased in hippocampus during aging [15]. Thus, our findings
about the induction of IDE and NEP levels by treatment with C-
CM indicate that the metabolites of neurons may attribute to the
difference in IDE and NEP levels between cerebellum and
hippocampus. The improvements in cognitive function by
metabolites of cerebellar neurons could not be attributed to
nonspecific effects on cognition because neither C-CM nor CSF-
4V had an effect on the performance of non-transgenic mice (data
not shown). The improvement in performance could also not be
attributed to nutritional or caloric effects because body weight,
activity and coat condition were not different between the groups.
Thus, the reversal of Alzheimer’s disease-like phenotypes is a result
of the significant reduction in brain Ab levels in APP/PS1 mice
treated with metabolites of cerebellar neurons. The levels of Ab
are determined by the balance between its generation and
clearance [16,17]. Ab is generated from Ab precursor protein
(APP) through two sequential proteolytic cleavages by b-secretase
and c-secretase [18] and is cleared either through receptor-
mediated efflux across the blood-brain barrier (BBB) [19,20] or via
peptidolytic mechanisms [21]. Metabolites of cerebellar neurons
did not accelerate the clearance of Ab across the BBB because the
levels of peripheral plasma Ab were remained unchanged (Table
S2 and Fig. S1). It is also not possible that metabolites may have
contained Ab degrading enzymes because incubation with C-CM
alone did not lead to Ab clearance (Fig. S2). So, metabolites of
cerebellar neurons protect against AD pathogenesis by reducing
Ab accumulation via Ab degrading enzymes.
According to recent evidence, the expression of NEP and IDE
are up-regulated by treatment with ciliary neurotrophic factor
(CNTF) [22] and IL4 [23]. IDE is also induced by insulin signal
pathway through phosphatidylinoesitol 3-kinase [24]. Thus, the
metabolites of cerebellar neurons could contain some neurotrophic
factors or small molecules which could activate insulin pathway.
We also investigate the molecular identity of the metabolites
derived from the conditioned medium. Firstly, the conditioned
medium was separated to two parts by ultra filter. One contains
molecules larger than 5 kD (Heavy) and the other are composed of
molecules smaller than 5 kD (Light). Then, neurons were treated
with these two parts of conditioned medium respectively and
according to the Western blot results, the Heavy part of
conditioned medium showed little effect on IDE and NEP
expression. Conversely, the Light part markedly repeated the
effect of total conditioned medium.
Next, we focused on the Light part of conditioned medium and
extracted the hydrophobic composition by organic extraction and
treated neurons with the hydrophobic and hydrophilic composi-
tion respectively. While the hydrophilic part showed little function
on IDE and NEP expression, the hydrophobic part completely
repeated the effect of total conditioned medium. Based on these
results, it is suggested that the active ingredient should be
hydrophobic molecule(s) with molecular weight less than 5 kD.
Further analysis of these compounds is currently being conducted.
Conversely, metabolites of hippocampal neurons significantly
reduced the expression of Ab degrading enzymes and induced
cerebellar Ab levels. Finally, metabolites of hippocampal neurons
caused cerebellar neurodegeneration in APP/PS1 transgenic mice.
It is known that the cerebrospinal fluid (CSF) was primarily
generated and secreted by the choroid plexuses (CP) and
approximately 10–20% was arised from the brain interstitial fluid,
which contains metabolites of neurons [25]. The circulation of
CSF is one-direction. CSF flows from the lateral ventricles via the
foramina of Monro into the third ventricle, and then the fourth
ventricle via the cerebral aqueduct in the brainstem. The location
of the choroid plexuses in the lateral, third, and fourth ventricles
allows for the possibility of new components being added to the
fluid at these points [26]. There is also active exchange of
substances between the CSF and its surrounding neurons, for
example, CSF-contacting neurons which are located periventri-
cularly or inside the brain ventricles. Thus, after a series of
substances exchange, the components of the CSF from lateral
ventricle (LV) and the fourth ventricle (4V) maybe different.
Moreover, previous evidence show that Na levels in the fourth
ventricle are statistically different from those in lateral ventricle
[27]. Taken together, the findings about the effect of 4V-CSF on
the Ab levels of APP/PS1 transgenic mice and their learning and
memory function could reflect the function of in vivo neuronal
metabolites.As we all known, the level of Ab is determined by the
balance between its generation and turnover [16]. In familial
Alzheimer’s disease (FAD), Ab accumulation is caused by
misprocessing of amyloid precursor protein (APP) [28]. However,
in the great majority of AD, the sporadic late-onset AD (LOAD), it
is decreased Ab clearance that contributes to the pathological
changes of the disease [29]. According to our study, the role of
metabolites of neurons in AD pathogenesis is closely associated
with Ab degradation, thus, could be beneficial to the clinical
therapy for AD patients.
Materials and Methods
Animals
All animal experiments were conducted according to the
guidelines established by the NIH Guide for the Care and Use
of Laboratory Animals. APP/PS1 transgenic mice of C57BL/6J
background and wild-type littermates, were purchased from the
Chinese Academy of Medical Science. Cerebrospinal fluid was
extracted and collected from the lateral ventricle and fourth
ventricles of wild-type C57BL/6J mice with a brain solid
positioner placed consistent with the brain atlas. Conditioned
medium and CSF was injected into the lateral ventricle of APP/
PS1 transgenic mice and wild-type littermates (n=6 to 10 mice in
each treatment group) with a brain solid positioner. 12 month old
APP/PS1 transgenic mice were used for the conditioned medium
injection; both 4 month old and 12 month old APP/PS1
transgenic mice were used for the CSF injection. Seven days after
injection, mice were tested for learning and memory abilities and
were then sacrificed for tissue collection.
Behavioral tests and data analysis
In all behavioral tests, the experimenter was ‘blind’ to the
groups to which the individual mice belonged [30].
The detailed method for the Morris water maze has been
described previously [31]. Training was performed four times per
day for 5 days. One day after the final training, the platform was
removed from the pool and each mouse received one 60 s test
[32]. The swimming trace was recorded and analyzed for each
mouse. The passive avoidance test has been described in detail
[33]. Mice were placed one at a time into the illuminated side of a
two-compartment apparatus. Upon entering the dark compart-
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they returned to the light compartment up to a maximum of 5 s.
The retention test took place 24 h after training with the shocker
switched off and a maximum latency of 300 s [34].
The detailed method for the pole test has been described
previously [31]. The mouse was placed head upward on the top of
a vertical iron rough-surfaced pole (diameter 1 cm, height 50 cm).
The times taken to turn completely downwards and then to
descend to the platform were recorded (with the cut-off limit of
5 min).
In balance beam test, mice were placed on a wooden beam
(diameter 1.5 cm, length 40 cm). The beam was elevated 50 cm
from the ground and was ended near a home cage. The latencies
of mice to get into the home cage were recorded.
Analysis of Ab burden in brain
Hemi-brains were removed from mice brains and fixed in
acetone. Then hemispheres were cut using a freezing microtome.
Ab plaque burden was detected using thioflavin-S [35] staining or
a polyclonal Ab antibody (diluted 1:100, Cell signaling) and the
digital image was analyzed using Image J software (NIH).
Plasma and cerebral Ab content
We homogenized the hippocampus and cerebral cortex in TBS
with the protease inhibitors. Homogenates were centrifuged and
supernatants from the TBS extraction were stored as soluble Ab
while the pellets were resuspended in a 5 mol/L guanidine HCl
and 50 mol/L Tris-HCl (pH 8.0) buffer and stored as insoluble
Ab. Samples were aliquoted and stored at 280uC and analyzed
for Ab40 and Ab42 using an ELISA kit (USCN Life), according to
the manufacturer’s protocol. Briefly, protein samples and the
detector antibody were incubated with the first Ab antibody pre-
coated on plates for 3 hours at room temperature. After washing,
secondary antibody was incubated for 30 minutes. Finally,
colorimetric reaction was conducted and absorbance on a
spectrophotometer (Bio-Rad Laboratories) at 450 nm was record-
ed.
Quantification of gliosis
Five randomly selected, evenly spaced sagittal sections were
collected from acetone-fixed and frozen hemispheres of treated
and control mice. A polyclonal glial fibrillary acid protein antibody
(diluted 1:100, Santa Cruz Biotechnology) was used to immuno-
label astrocytes and a polyclonal CD68 antibody (diluted 1:100,
Santa Cruz Biotechnology) was used to detect microglia. Digital
images were captured using a digital camera mounted to a
microscope. Images were analyzed using Image-Pro Plus 5.0
software.
Quantification of synaptophysin
Immunohistochemical staining for synaptophysin was per-
formed on three evenly spaced sections of acetone-fixed treated
and control mice. A polyclonal synaptophysin antibody (diluted
1:100, Santa Cruz Biotechnology)was used to immunolabel the
synaptophysin. Digital images were captured and analyzed as
described above.
Primary neuronal culture
The hippocampus, cerebral cortex and cerebellum were
dissected from brains of embryonic day 18 (E18) Sprague Dawley
rats and digested with 0.25% trypsin to obtain dissociated cells.
The resultant cells were cultured in Neurobasal medium (NBM)
supplemented with B27 at 37uCi n5 %C O 2. Glial cells were not
observed by microscopy in the neuronal cultures at the time of the
experiment.
Preparation of conditioned medium
Primary neurons after 7 to 10 DIC (days of in vitro culture) were
washed three times with B27-free Neurobasal medium and
incubated with B27-free Neurobasal medium for 48 hr. The
medium was collected and centrifuged at 800 g (4uC) to remove
cellular debris, then aliquoted and stored at 280uC. For injection
to APP/PS1 transgenic mice, the conditioned medium was pre-
concentrated 30-fold (from 45 ml to 1.5 ml) using a Centricon 100
concentrator device (Christ, German) and then aliquoted and
stored at 280uC.
Real-time PCR
Brain tissues were homogenized and total RNA was isolated
using Trizol (Invitrogen). The primers for APP, BACE1, PS1,
NEP and IDE SYBR Green PCR were purchased from
Invitrogen. Real-Time PCR was performed by Mx3000P
(Stratagene).
Western immunoblotting
Samples were resolved by SDS-PAGE and transferred to a
PVDF membrane. The membrane was blocked for 1.5 h in 5%
nonfat milk and incubated with primary antibodies for Ab
(polyclonal antibody, diluted 1:200, Sigma), NEP (polyclonal
antibody, diluted 1:500, Millipore), IDE (monoclonal antibody,
diluted 1:2000, Abcam) and actin (polyclonal antibody, diluted
1:500, Santa Cruz Biotechnology). The membranes were then
incubated with horseradish peroxidase-conjugated anti-mouse IgG
or anti-rabbit IgG. Finally, the membranes were developed by a
Kodak medical X-ray processor (Kodak).
Chemicals and statistical analyses
Human Ab 1-40 and Thioflavin-S were purchased from Sigma.
Data are presented as group means6SEM. A value of P,0.05 was
considered significant. One-way analysis of variance (ANOVA)
was used to evaluate the differences between the experimental
groups.
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